Decursinol angelate
Based on 1 publication(s) in Google Scholar
Decursinol angelate acts as a PKC activator and GDH inhibitor, with an IC50 of 1.432 μM against human GDH. Decursinol angelate activates PKC, downregulates PKCα and PKCβII isoforms, and exerts cytotoxic activity against cancer cells. Decursinol angelate binds to GDH and inhibits its enzymatic activity. Decursinol angelate inhibits VEGF-induced autophosphorylation of VEGFR2, downstream p42/44 ERK and JNK-MAPK signaling pathways, as well as the angiogenesis process. Decursinol angelate is applicable to research related to cancer and leukemia.
For research use only. We do not sell to patients.
- Purity : 99.94%
- CAS No.: 130848-06-5
- Formula: C19H20O5
- Molecular Weight:328.36
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-N0643
CarnosolEndogenous Metabolite -
HY-N0865
IngenolPKC Activator -
HY-N0699
DaphnoretinPKC Activator -
HY-N6843
Arnicolide DAntitumor Agent -
HY-N1318
SalvigeninAnticancer Agent -
HY-13434
IonomycinCalcium Ionophore -
HY-18739
Phorbol 12-myristate 13-acetatePKC Activator -
HY-N4322R
Decursinol angelate (Standard)PKC Activator -
HY-13689
Go 6983PKC Inhibitor -
HY-13867
Bisindolylmaleimide IPKC Inhibitor -
HY-18739R
Phorbol 12-myristate 13-acetate (Standard)PKC Activator -
HY-B0719
Ingenol MebutatePKC Modulator
Publications Citing Use of MedChemExpress (MCE) Decursinol angelate
More
Biological Activity
Description
IC50 & Target
PKC[1].
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| B16 | IC50 |
5.8 μg/mL
Compound: 6
|
Inhibition of alpha-MSH-stimulated melanogenesis in mouse B16 cells assessed as melanin release after 72 hrs
Inhibition of alpha-MSH-stimulated melanogenesis in mouse B16 cells assessed as melanin release after 72 hrs
|
[PMID: 22450129] |
In Vitro
Decursinol angelate (20 μg/mL) exhibits cytotoxic activity across multiple human cancer cell lines with an ED50 <20 μg/mL and activates protein kinase C[1].
Decursinol angelate inhibits VEGF-induced angiogenesis in HUVECs by targeting the VEGFR2 signaling pathway[1].
Decursinol angelate potently inhibits human glutamate dehydrogenase with an IC50 of 1.432 μM[1].
Decursinol angelate inhibits melanin synthesis in B16 murine melanoma cells[1].
Decursinol angelate potently inhibits androgen receptor signaling in vitro, but is rapidly metabolized to the less active decursinol in vivo[1].
Decursinol angelate downregulates cytochrome P450 2A6 activity in human liver microsomes[1].
Decursinol angelate (20-40 μM) inhibits the expression and secretion of pro-inflammatory cytokines IL-1β and IL-6 in PMA-differentiated HL-60 cells, with no effect on IL-4 or IL-10 expression[3].
Decursinol angelate (20-40 μM) inhibits PMA-induced activation of the NFκB pathway and Raf-ERK MAPK pathway (but not the p38/JNK pathway) in PMA-differentiated HL-60 and Raw 264.7 cells[3].
Decursinol angelate (30 μM; 24 h) inhibits LPS-induced pro-inflammatory cytokine production, M1 marker expression, and macrophage polarization in Raw 264.7 cells[3].
Decursinol angelate (20-40 μM) inhibits LPS-induced NFκB translocation and MAPK pathway activation in Raw 264.7 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:LPS-stimulated mouse macrophage Raw 264.7 cells
-
Concentration:30-40 μM (NFκB translocation Western blot); 20-40 μM (MAPK pathway Western blot)
-
Incubation Time:null (NFκB translocation Western blot; MAPK pathway Western blot)
-
Result:Blocked LPS-induced activation of NFκB subunits p50 and p65.
Inhibited LPS-induced translocation of NFκB p65 from the cytoplasm to the nucleus.
Inhibited LPS-induced activation of the MAPK pathway, reducing phosphorylation of p38, ERK, and JNK.
In Vivo
Decursinol angelate (50-100 mg/kg; i.p.; daily; 9 consecutive days) inhibits the growth of subcutaneous Sarcoma-180 solid tumors in mice, producing 39.5-40.6% tumor volume reduction and 31.0-35.2% tumor weight reduction at 50 mg/kg and 100 mg/kg, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR mice (male, 4-week-old, 23±2 g, intraperitoneally inoculated with Sarcoma-180 ascitic tumor cells)[2]
-
Dosage:50 mg/kg; 100 mg/kg
-
Administration:i.p.; daily; 9 consecutive days
-
Result:Increased median survival time to 32.3 days, corresponding to a 44.2% increase in life span .
Increased median survival time to 34.2 days, corresponding to a 52.7% increase in life span .
-
Animal Model:ICR mice (male, 4-week-old, 23±2 g, subcutaneously transplanted with Sarcoma-180 solid tumor cells)[2]
-
Dosage:50 mg/kg; 100 mg/kg
-
Administration:i.p.; daily; 9 consecutive days
-
Result:Reduced solid Sarcoma-180 tumor volume by 39.5% to 3768.8 mm3 and reduced tumor weight by 35.2% to 4.6 g.
Reduced solid Sarcoma-180 tumor volume by 40.6% to 3700.3 mm3 and reduced tumor weight by 31.0% to 4.9 g.
Chemical Information
-
CAS No. 130848-06-5
-
Appearance Solid
-
Molecular Weight 328.36
-
Formula C19H20O5
-
Color White to off-white
-
SMILES
C/C=C(C)\C(O[C@H]1CC(C=C(C=CC(O2)=O)C2=C3)=C3OC1(C)C)=O
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (304.54 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (7.61 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.61 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sestito S, et al. Anticancer potential of decursin, decursinol angelate, and decursinol from Angelica gigas Nakai: A comprehensive review and future therapeutic prospects. Food Sci Nutr. 2024;12(10):6970-6989. Published 2024 Jul 31. [Content Brief]
[2]. Lee S, et al. Anti-tumor activities of decursinol angelate and decursin from Angelica gigas. Arch Pharm Res. 2003;26(9):727-730. [Content Brief]
[3]. Islam SU, et al. Decursinol Angelate Inhibits LPS-Induced Macrophage Polarization through Modulation of the NFκB and MAPK Signaling Pathways. Molecules. 2018;23(8):1880. Published 2018 Jul 27. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0454 mL | 15.2272 mL | 30.4544 mL | 76.1360 mL |
| 5 mM | 0.6091 mL | 3.0454 mL | 6.0909 mL | 15.2272 mL | |
| 10 mM | 0.3045 mL | 1.5227 mL | 3.0454 mL | 7.6136 mL | |
| 15 mM | 0.2030 mL | 1.0151 mL | 2.0303 mL | 5.0757 mL | |
| 20 mM | 0.1523 mL | 0.7614 mL | 1.5227 mL | 3.8068 mL | |
| 25 mM | 0.1218 mL | 0.6091 mL | 1.2182 mL | 3.0454 mL | |
| 30 mM | 0.1015 mL | 0.5076 mL | 1.0151 mL | 2.5379 mL | |
| 40 mM | 0.0761 mL | 0.3807 mL | 0.7614 mL | 1.9034 mL | |
| 50 mM | 0.0609 mL | 0.3045 mL | 0.6091 mL | 1.5227 mL | |
| 60 mM | 0.0508 mL | 0.2538 mL | 0.5076 mL | 1.2689 mL | |
| 80 mM | 0.0381 mL | 0.1903 mL | 0.3807 mL | 0.9517 mL | |
| 100 mM | 0.0305 mL | 0.1523 mL | 0.3045 mL | 0.7614 mL |
Decursinol angelate Related Classifications
HY-N4322 Related Classifications
Powered by Bioz